Quoin Pharmaceuticals Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Quoin Pharmaceuticals Ltd (QNRX) reported its Q3 2025 financial results, highlighting a net loss of $3.9 million, attributed to increased R&D expenses. The company secured a private placement financing of up to $105.3 million and appointed Sally Lawlor as CFO. Quoin received Orphan Drug Designation for QRX003 and is expanding its pediatric Netherton clinical program. The NETHERTON NOW campaign has garnered over 1.5 million views. With a strong cash position, Quoin is set to support operations into 2027 while advancing its clinical programs for rare diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments